Cheng-Pang Hou

Papers

Total Citations

H-Index

About

Cheng-Pang Hou is a urological surgeon and researcher whose work focuses on improving outcomes for patients with high-risk prostate cancer. His key research areas include robotic-assisted surgery, neoadjuvant hormone therapy, and the optimization of multimodal treatment strategies for aggressive prostate malignancies. Hou’s major contribution lies in demonstrating that neoadjuvant hormone therapy, when combined with robotic-assisted radical prostatectomy, can yield favorable oncologic outcomes in high-risk patients—a population traditionally facing higher rates of positive surgical margins and biochemical recurrence. His most-cited study, published in 2014, has accumulated 5 citations and provides early evidence supporting the integration of preoperative hormonal manipulation with minimally invasive surgical techniques. This work has helped shape clinical conversations around the timing and sequencing of therapies for advanced prostate cancer. Hou’s research bridges the gap between surgical innovation and systemic treatment, offering a more nuanced approach to managing high-risk disease. His findings continue to inform urologists and oncologists seeking to reduce recurrence and improve survival in challenging cases, making him a thoughtful contributor to the evolving landscape of prostate cancer care.